151 related articles for article (PubMed ID: 27436336)
1. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.
Ostronoff F; Othus M; Lazenby M; Estey E; Appelbaum FR; Evans A; Godwin J; Gilkes A; Kopecky KJ; Burnett A; List AF; Fang M; Oehler VG; Petersdorf SH; Pogosova-Agadjanyan EL; Radich JP; Willman CL; Meshinchi S; Stirewalt DL
J Clin Oncol; 2015 Apr; 33(10):1157-64. PubMed ID: 25713434
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia.
Tarlock K; Gerbing RB; Ries RE; Smith JL; Leonti A; Huang BJ; Kirkey D; Robinson L; Peplinksi JH; Lange B; Cooper TM; Gamis AS; Kolb EA; Aplenc R; Pollard JA; Alonzo TA; Meshinchi S
Blood Adv; 2024 May; 8(9):2094-2103. PubMed ID: 38295280
[TBL] [Abstract][Full Text] [Related]
5. Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients.
Chen M; Zeng Z; Li X; Qin W; Cai X; Chen S; Lu X
Int J Lab Hematol; 2023 Dec; 45(6):899-907. PubMed ID: 37519024
[TBL] [Abstract][Full Text] [Related]
6. Distinct karyotypic and mutational landscape in trisomy AML.
Lam SSY; Tsui SP; Fung CY; Saw NY; Javed A; Ip AHW; Ma ESK; Leung AYH
Br J Haematol; 2024 Mar; 204(3):939-944. PubMed ID: 38054248
[TBL] [Abstract][Full Text] [Related]
7. [Gene Profile and Clinical Significance of Concomitant Mutations in CN-AML Patients with
Zhu J; Kang YF; Gao Y; Wang HW; Hao ZH; Wang HW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):335-341. PubMed ID: 38660833
[TBL] [Abstract][Full Text] [Related]
8. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
Tarlock K; Lamble AJ; Wang YC; Gerbing RB; Ries RE; Loken MR; Brodersen LE; Pardo L; Leonti A; Smith JL; Hylkema TA; Woods WG; Cooper TM; Kolb EA; Gamis AS; Aplenc R; Alonzo TA; Meshinchi S
Blood; 2021 Sep; 138(13):1137-1147. PubMed ID: 33951732
[TBL] [Abstract][Full Text] [Related]
9. C/EBPα and MYB regulate FLT3 expression in AML.
Volpe G; Walton DS; Del Pozzo W; Garcia P; Dassé E; O'Neill LP; Griffiths M; Frampton J; Dumon S
Leukemia; 2013 Jul; 27(7):1487-96. PubMed ID: 23340802
[TBL] [Abstract][Full Text] [Related]
10. Blasts with folded nuclei: A histopathologic finding in myeloid leukemia cutis with NPM1 and FLT3 mutations.
Han S; Patel T; Garcia ML; Tirado M
J Cutan Pathol; 2024 Feb; 51(2):130-134. PubMed ID: 37866827
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and Outcome of FLT3-ITD-Positive Pediatric Acute Myeloid Leukemia-Experience of Polish Pediatric Leukemia and Lymphoma Study Group from 2005 to 2022.
Czogała M; Czogała W; Pawińska-Wąsikowska K; Książek T; Bukowska-Strakova K; Sikorska-Fic B; Łaguna P; Fałkowska A; Drabko K; Muszyńska-Rosłan K; Krawczuk-Rybak M; Kozłowska M; Irga-Jaworska N; Zielezińska K; Urasiński T; Bartoszewicz N; Styczyński J; Skalska-Sadowska J; Wachowiak J; Rodziewicz-Konarska A; Kałwak K; Ciebiera M; Chaber R; Mizia-Malarz A; Chodała-Grzywacz A; Karolczyk G; Bobeff K; Młynarski W; Mycko K; Badowska W; Tomaszewska R; Szczepański T; Machnik K; Zamorska N; Balwierz W; Skoczeń S
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760526
[TBL] [Abstract][Full Text] [Related]
12. Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia.
Oya S; Ozawa H; Maehiro Y; Nakamura T; Takaki Y; Fukuyama T; Yamasaki Y; Yamaguchi M; Aoyama K; Mouri F; Nagafuji K
Leuk Res; 2023 Jul; 130():107313. PubMed ID: 37207502
[No Abstract] [Full Text] [Related]
13. Clinical features and management of germline CEBPA-mutated carriers.
Pan L; Li Y; Gao H; Lai X; Cai Y; Chen Z; Li X; Wang SY
Leuk Res; 2024 Mar; 138():107453. PubMed ID: 38442594
[TBL] [Abstract][Full Text] [Related]
14. Profiling
Molina Garay C; Carrillo Sánchez K; Flores Lagunes LL; Jiménez Olivares M; Muñoz Rivas A; Villegas Torres BE; Flores Aguilar H; Núñez Enríquez JC; Jiménez Hernández E; Bekker Méndez VC; Torres Nava JR; Flores Lujano J; Martín Trejo JA; Mata Rocha M; Medina Sansón A; Espinoza Hernández LE; Peñaloza Gonzalez JG; Espinosa Elizondo RM; Flores Villegas LV; Amador Sanchez R; Pérez Saldívar ML; Sepúlveda Robles OA; Rosas Vargas H; Rangel López A; Domínguez López ML; García Latorre EA; Reyes Maldonado E; Galindo Delgado P; Mejía Aranguré JM; Alaez Verson C
Front Pediatr; 2020; 8():586. PubMed ID: 33042924
[No Abstract] [Full Text] [Related]
15. Gene regulation in t(6;9) DEK::NUP214 Acute Myeloid Leukemia resembles that of FLT3-ITD/NPM1 Acute Myeloid Leukemia but with an altered HOX/MEIS axis.
Potluri S; Kellaway SG; Coleman DJL; Keane P; Imperato MR; Assi SA; Cockerill PN; Bonifer C
Leukemia; 2024 Feb; 38(2):403-407. PubMed ID: 38172329
[No Abstract] [Full Text] [Related]
16. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.
Mrózek K; Kohlschmidt J; Blachly JS; Nicolet D; Carroll AJ; Archer KJ; Mims AS; Larkin KT; Orwick S; Oakes CC; Kolitz JE; Powell BL; Blum WG; Marcucci G; Baer MR; Uy GL; Stock W; Byrd JC; Eisfeld AK
Leukemia; 2023 Apr; 37(4):788-798. PubMed ID: 36823396
[TBL] [Abstract][Full Text] [Related]
17. AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.
Zhao D; Zhou Q; Zarif M; Eladl E; Wei C; Atenafu EG; Schuh A; Tierens A; Yeung YWT; Minden MD; Chang H
Leuk Res; 2023 Nov; 134():107376. PubMed ID: 37690321
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Molecular Profiling of NPM1-Mutated Acute Myeloid Leukemia Using RNAseq Approach.
Petiti J; Pignochino Y; Schiavon A; Giugliano E; Berrino E; Giordano G; Itri F; Dragani M; Cilloni D; Lo Iacono M
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612443
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of CEBPA mutational subgroups in adult AML.
Georgi JA; Stasik S; Kramer M; Meggendorfer M; Röllig C; Haferlach T; Valk P; Linch D; Herold T; Duployez N; Taube F; Middeke JM; Platzbecker U; Serve H; Baldus CD; Muller-Tidow C; Haferlach C; Koch S; Berdel WE; Woermann BJ; Krug U; Braess J; Hiddemann W; Spiekermann K; Boertjes EL; Hills RK; Burnett A; Ehninger G; Metzeler K; Rothenberg-Thurley M; Dufour A; Dombret H; Pautas C; Preudhomme C; Fenwarth L; Bornhäuser M; Gale R; Thiede C
Leukemia; 2024 Feb; 38(2):281-290. PubMed ID: 38228680
[TBL] [Abstract][Full Text] [Related]
20. FLT3-targeted therapy restores GATA1 pathway function in NPM1/FLT3-ITD mutated acute myeloid leukaemia.
Sorcini D; Stella A; Scialdone A; Sartori S; Marra A; Rossi R; De Falco F; Adamo FM; Dorillo E; Geraci C; Arcaleni R; Rompietti C; Esposito A; Moretti L; Mameli MG; Martelli MP; Falini B; Sportoletti P
EJHaem; 2023 Nov; 4(4):1100-1104. PubMed ID: 38024637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
